Publication:
Current State of Omics Biomarkers in Pancreatic Cancer

Simple item page
dc.contributor.authorTURANLI, BESTE
dc.contributor.authorsTuranli, Beste; Yildirim, Esra; Gulfidan, Gizem; Arga, Kazim Yalcin; Sinha, Raghu
dc.date.accessioned2022-03-10T11:40:12Z
dc.date.available2022-03-10T11:40:12Z
dc.date.issued2021-02-14
dc.description.abstractPancreatic cancer is one of the most fatal malignancies and the seventh leading cause of cancer-related deaths related to late diagnosis, poor survival rates, and high incidence of metastasis. Unfortunately, pancreatic cancer is predicted to become the third leading cause of cancer deaths in the future. Therefore, diagnosis at the early stages of pancreatic cancer for initial diagnosis or postoperative recurrence is a great challenge, as well as predicting prognosis precisely in the context of biomarker discovery. From the personalized medicine perspective, the lack of molecular biomarkers for patient selection confines tailored therapy options, including selecting drugs and their doses or even diet. Currently, there is no standardized pancreatic cancer screening strategy using molecular biomarkers, but CA19-9 is the most well known marker for the detection of pancreatic cancer. In contrast, recent innovations in high-throughput techniques have enabled the discovery of specific biomarkers of cancers using genomics, transcriptomics, proteomics, metabolomics, glycomics, and metagenomics. Panels combining CA19-9 with other novel biomarkers from different omics levels might represent an ideal strategy for the early detection of pancreatic cancer. The systems biology approach may shed a light on biomarker identification of pancreatic cancer by integrating multi-omics approaches. In this review, we provide background information on the current state of pancreatic cancer biomarkers from multi-omics stages. Furthermore, we conclude this review on how multi-omics data may reveal new biomarkers to be used for personalized medicine in the future.
dc.identifier.doi10.3390/jpm11020127
dc.identifier.eissn2075-4426
dc.identifier.pubmed33672926
dc.identifier.urihttps://hdl.handle.net/11424/219975
dc.identifier.wosWOS:000622683700001
dc.language.isoeng
dc.publisherMDPI
dc.relation.ispartofJOURNAL OF PERSONALIZED MEDICINE
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectpancreatic cancer
dc.subjectsystems biology
dc.subjectomics
dc.subjectbiomarker
dc.subjectgenomics
dc.subjecttranscriptomics
dc.subjectproteomics
dc.subjectmetabolomics
dc.subjectglycomics
dc.subjectmetagenomics
dc.subjectpersonalized medicine
dc.titleCurrent State of Omics Biomarkers in Pancreatic Cancer
dc.typereview
dspace.entity.typePublication
local.avesis.ideb180767-dab8-4a67-901f-962dda728bef
local.import.packageSS4
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.journal.articlenumber127
local.journal.numberofpages24
oaire.citation.issue2
oaire.citation.titleJOURNAL OF PERSONALIZED MEDICINE
oaire.citation.volume11
relation.isAuthorOfPublication3e8c4f64-93ae-4b42-953c-35c8b07586b3
relation.isAuthorOfPublication.latestForDiscovery3e8c4f64-93ae-4b42-953c-35c8b07586b3

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Turanli et al. - 2021 - Current State of “Omics” Biomarkers in Pancreatic .pdf
Size:
702.57 KB
Format:
Adobe Portable Document Format
Download

Collections

Research Outputs